Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05611112
Other study ID # PST
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date November 1, 2022
Est. completion date March 1, 2025

Study information

Verified date November 2023
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Denmark the vast majority of patients with chronic ischemic heart disease and/or type 2 diabetes are managed in general practice. 20% of the patients suffer from poor mental health. Problem-solving therapy (PST) is a psychotherapeutic method that is proven effective in adults with poor mental health. PST can be provided in general practice. The main objective of this study is to test effectiveness of providing PST to this group patients.


Description:

20% of patients with type 2 diabetes and/or chronic ischemic heart disease have poor mental health. Since these patients are managed in general practice interventions targeting poor mental health in these patients should be delivered in here. Problem-solving therapy (PST) is a well-established psychotherapeutic method that can be delivered by health care providers in general practice. The main objective of this study is to test the effectiveness of delivering PST for patients with T2D and/or IHS who suffer from poor mental health. We hypothesize that the patients' mental health will be improved after treatment with PST. Health care providers from 12 general practices are trained in PST and subsequently provide PST for patients with T2D and/or IHS and poor mental health. Patients are recruited at the annual control visit for the chronic disease. All patients are screened for impaired mental health with the WHO-5 questionnaire. Patients with a score below 50 are offered PST. The study is conducted as a stepped wedge cluster-randomised controlled trial with a one-year follow-up. In this design clusters are stepped wise exposed to the intervention. Initially all general practices are in the control group. After four months half of the recruited GPs attend the PST training programme and switch to performing the intervention. After an additional four months the remaining GPs are educated in PST and all GPs now perform the intervention. Both general practitioners and practise nurses will perform PST consultations. The power calculation is based on: - The primary outcome (PHQ-9 score at 6 and 12 months. The minimal clinical effect is 5 points) - ICC is estimated to 0,05. Based on these assumptions we will include 188 patients with IHS or/and T2D (we expect 25% overlap) to obtain a power of 90%.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 188
Est. completion date March 1, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - +18 years - Diagnosed with ischemic heart disease and/or type 2 diabetes - Poor mental health defined as WHO-5 well-being index <50 points Exclusion Criteria: - severe mental illness including psychotic disease and suicidal behaviour - unable to read and understand Danish

Study Design


Intervention

Behavioral:
Problem Solving Therapy
Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.

Locations

Country Name City State
Denmark Research unit for general practice Aarhus

Sponsors (5)

Lead Sponsor Collaborator
University of Aarhus Central Denmark Region, Danish Heart Foundation, Research Unit for General Practice, Aarhus University, TrygFonden, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mental health - Depression Patient Health Questionnaire-9 (PHQ-9) at 12 months of follow-up 12 months
Secondary Mental health - Anxiety General Anxiety Disorder-7 (GAD-7) 12 months of follow-up 12 months
Secondary Mental health - Anxiety General Anxiety Disorder-7 (GAD-7) 6 months of follow-up 6 months
Secondary Diabetes related stress Problem Areas in Diabetes-5 (PAID-5) at 12 months of follow-up 12 months
Secondary Mental health - Depression Patient Health Questionnaire-9 (PHQ-9) at 6 months of follow-up 6 months
Secondary Prescriptions of psychopharmacological medications Prescriptions of psychopharmacological medications during one year after start of patient-inclusion. Register-based. 12 months
Secondary Medication adherence Changes in medication adherence to antidiabetic drugs and statins Baseline and 12 months
Secondary Lipid profile Changes in lipid profile (from blod samples) Baseline and 12 months
Secondary Blood pressure Changes in blod pressure Baseline and 12 months
Secondary Smoking status Changes in smoking status Baseline and 12 months
Secondary Use of health care services Changes in use of health care services including any contacts to general practice, out-of-hours medical service, cardiovascular readmissions and all cause hospitalizations Baseline and 12 months
Secondary Health literacy Data on health literacy will be collected at baseline using the HLSAC instrument (Health Literacy for School-Aged Children), which allows the calculation of a health literacy summary score used to examine health literacy levels. HLSAC is currently being validated among adults. The summary score is between 10-40 points: 10-25 points indicates low health literacy, 26-35 points indicates moderate health literacy, 26-40 points indicates high health literacy. Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02759406 - Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A